MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - April 02, 2012) -
MorphoSys AG /
MorphoSys to Start Share Buy-Back Program.
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced
decision to repurchase its own shares on the stock market. Following
the Company's Supervisory Board, the Board of Management of MorphoSys
resolved to acquire up to 100,000 MorphoSys shares over the stock market
the time period from April 1, 2012 to April 30, 2012. The shares will be
implement the Company's long-term incentive program 2012 for its
The relevant conditions of the shareholders' resolutions passed in the
shareholders' meeting 2011 of MorphoSys AG on the authorization to
to use its own shares shall apply. The purchase price paid per share may
more than 10 % higher or 20 % lower than the Company's share price
the opening auction in the Xetra trading system on the day of trading.
basis of the current share price (status: March 30, 2012), this would
around EUR 1.76 million or up to 0.4% of the share capital.
The buy-back is to be handled independently of and uninfluenced by the
through an appointed bank in compliance with the safe-harbor provisions.
MorphoSys will provide regular information on the progress of the share
program on the Company's website www.morphosys.com.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
on engineering the medicines of tomorrow. MorphoSys is listed on the
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,
RapMAT® and arYla® are
registered trademarks of MorphoSys AG. Ylanthia® and 100
potentialsTM are trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE